Parissa Tabrizian

The rise of transplant oncology in primary liver cancer and metastatic disease.

Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study

Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study

Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study.

Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study.

Initial Efforts to Stratify Patients and Donors Utilizing Normothermic Machine Preservation of Livers for Transplant.

Treating Donation After Circulatory Death Liver Grafts With Alteplase During Ex Situ Normothermic Machine Perfusion.

Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma

Integrating immune check inhibitors in liver transplantation for hepatocellular carcinoma: The right time and the right patient

Sociodemographic disparities in downstaging to liver transplant for hepatocellular carcinoma

Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium

Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium.

Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the “all-comers” protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium

Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.

Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma

Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma

Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium

PD-1 inhibitor as bridge therapy to liver transplantation?

De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management—Guidelines From the ILTS-SETH Consensus Conference

Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma

Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer.

Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma

Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi‐center retrospective cohort study

Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors

Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma

Is it Time to Abandon the Milan Criteria?